Cytotoxic T lymphocyte-associated protein 4 (CTLA4)-specific immune-checkpoint blockers have been approved for melanoma treatment and derepress autophagic responses of DCs in the Treg-infiltrated TME. Here, CTLA4 is linked to melanoma.